- Financing co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners with significant participation from other new and existing investors
- Proceeds will support the ongoing clinical development of AGA2118, AGA2115, AGA111, and other pipeline assets
- Kevin Li, M.D., from Frazier Life Sciences will join the Board of Directors
WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals (“Angitia” or “the Company”), a clinical-stage biotechnology company developing novel therapies aimed at improving musculoskeletal health, today announced the closing of a $130 million Series D financing round. Frazier Life Sciences and Venrock Healthcare Capital Partners co-led the financing, with participation from new investors: Ascenta Capital, certain funds and accounts managed by Blackrock, BVF Partners, Logos Capital, RA Capital Management, and Wellington Management. Existing investors, Bain Capital Life Sciences, Elikon Venture, Janus Henderson Investors, 3H Health Investment, Hillhouse Investment, Legend Capital, Morningside Group, OrbiMed, TF Capital and Yonghua Capital, also participated. Proceeds from the Series D will support the continued development of Angitia’s robust pipeline of novel, differentiated investigational treatments for serious musculoskeletal diseases.
“This financing underscores the continued growth of Angitia, the quality of our emerging data, and the advancement of our clinical product candidates, as recently demonstrated with the completion of enrollment in our Phase 2 ARTEMIS trial in postmenopausal osteoporosis and the initiation of dosing in our Phase 2 IDUN trial in osteogenesis imperfecta,” said Dr. David Ke, M.D., Chief Executive Officer of Angitia. “We are excited and grateful to add another strong set of high-quality investors to our growing syndicate.”
In connection with the financing, Kevin Li, M.D., a Partner on the Frazier Life Sciences team, will join the Board of Directors. Dr. Li was previously a resident physician in Internal Medicine at Stanford University and a consultant at McKinsey & Company, where he focused on corporate strategy, growth and M&A in the hospital services and pharmaceutical industries. Dr. Li received his M.D. from Stanford University and his B.S. from Yale University, where he graduated summa cum laude in Molecular Biophysics and Biochemistry and was a member of Phi Beta Kappa.
About Angitia Biopharmaceuticals
Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing novel therapies aimed at improving musculoskeletal health. Angitia is currently developing three biologic product candidates (AGA2118, AGA2115 and AGA111) in the clinic for the treatment of postmenopausal osteoporosis, osteogenesis imperfecta and spinal fusion. Leveraging the team's extensive experience and scientific acumen in bone biology and musculoskeletal drug development, Angitia is committed to developing novel therapeutics based on rational biology and clearly defined unmet medical needs.
Learn more at www.angitiabio.com.
Investor & Media Contact:
William Windham
Solebury Strategic Communications
wwindham@soleburystrat.com
646-378-2946
Forward-Looking Statements
This press release is prepared by Angitia Biopharmaceuticals (the “Company”, “We”) for informational purposes only. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “anticipate”, “expect”, “intend”, “plan”, “believe”, “continue”, “could”, “potential”, “may”, “will”, “goal” or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words.
These forward-looking statements involve substantial known and unknown risks and uncertainties, including the risk that results in earlier clinical trials and preclinical studies may not be indicative of future results and that any product candidates may not ultimately obtain required approvals or meaningfully improve patient outcomes, and other factors that are beyond the Company’s control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law.
Except as expressly required by law, the Company and/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided.
